Abstract 2116P
Background
Body mass index (BMI) and waist circumference (WC) were used to evaluate nutritional status and obesity.We aimed to examine whether preoperative BMI or WC was associated with mortality after cancer surgery.
Methods
As a population-based cohort study, this study used data extracted from the National Health Insurance Service database of South Korea.We included 87,220 adult patients who underwent major cancer surgery with curative intent between January 1, 2016, and December 31, 2020.
Results
A total of 87,220 patients were included in the final analysis, and 1,374 (1.6%) died within 90 days after cancer surgery. In the multivariable logistic regression model, the BMI <18.5/kg/m2 and >35 kg/m2 groups showed 1.98-fold (odds ratio [OR]: 1.98, 95% confidence interval [CI]: 1.58, 2.49; P<0.001) and 2.62-fold (OR: 2.62, 95% CI: 1.26, 5.45; P<0.001) higher 90-day mortality after cancer surgery than did the BMI 18.5–24.9 kg/m2 group. The 25.0–29.9 kg/m2 (P=0.143) and 30.0–34.9 kg/m2 (P=0.109) BMI groups did not show significant differences compared to the BMI 18.5–24.9 kg/m2 group. Compared with the normal WC group, the high (P=0.052) and very high (P=0.236) WC groups also did not show significant differences in terms of 90-day mortality.
Table: 2116P
Subgroup analyses for 90-day mortality according to cancer surgery type
Surgery | OR (95% CI) | P-value |
Lung cancer | ||
BMI: <18.5 | 1.89 (1.08, 3.29) | 0.025 |
BMI: 25.0–29.9 | 0.82 (0.59, 1.14) | 0.235 |
BMI: 30.0–34.9 | 0.97 (0.37, 2.59) | 0.954 |
BMI: >35.0 | 5.91 (1.19, 29.312) | 0.030 |
Gastric cancer | ||
BMI: <18.5 | 2.47 (1.49, 4.10) | <0.001 |
BMI: 18.5–24.9 | 1 | |
BMI: 25.0–29.9 | 0.99 (0.70, 1.39) | 0.944 |
BMI: 30.0–34.9 | 0.32 (0.09, 1.11) | 0.072 |
BMI: >35.0 | 1.62 (0.20, 13.26) | 0.654 |
Colorectal cancer | ||
BMI: <18.5 | 2.36 (1.53, 3.65) | <0.001 |
BMI: 25.0–29.9 | 0.91 (0.68, 1.24) | 0.556 |
BMI: 30.0–34.9 | 1.01 (0.47, 2.19) | 0.979 |
BMI: >35.0 | 4.67 (1.23, 17.73) | 0.024 |
Liver cancer | ||
BMI: <18.5 | 2.22 (1.11, 4.43) | 0.024 |
BMI: 25.0–29.9 | 0.78 (0.52, 1.17) | 0.227 |
BMI: 30.0–34.9 | 0.62 (0.20, 1.94) | 0.409 |
BMI: >35.0 | 1.09 (0.12, 9.88) | 0.941 |
OR, Odds ratio; CI, confidence interval; BMI, body mass index; WC, waist circumference
Conclusions
Preoperative BMI <18.5 kg/m2 and >35 kg/m2 are associated with an elevated risk of 90-day mortality after major cancer surgery. However, preoperative WC was not significantly associated with 90-day mortality after cancer surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
N/A.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06